摘要: Two prospective randomized trauma trials have shown recombinant factor VIIa (rFVIIa) to be safe and to decrease transfusion requirements. rFVIIa is presently used in 22% of massively transfused civilian trauma patients. The US Mil... 展开
作者 | Wade, C. E. Eastridge, B. J. Jones, J. A. West, S. A. Spinella, P. C. Perkins, J. G. Dubick, M. A. Blackbourne, L. H. Holcomb, J. B. | ||
---|---|---|---|
原报告号 | ADA629434 | 总页数 | 8 |
主办者 | Non Paid ADAS | ||
报告分类号 | [ 57A - Anatomy, 57S - Physiology, 57E - Clinical Medicine, 57Q - Pharmacology &, Pharmacological Chemistry, 74 - Military Sciences] | ||
报告类别/文献类型 | AD / NTIS科技报告 | ||
关键词 | Anticoagulants Blood transfusion Wounds and injuries Blood cells Blood coagulation Blood pressure Casualties Coma(physiology) Death Demography Deployment Erythrocytes Heart rate Hemorrhagic shock Military medicine Military personnel Mortality rate Multivariate analysis Normalizing(statistics) Patients Physicians Random variables Reprints Trauma Warfare Recombinant factor viia Outcomes Combat casualties |